Toft Group Completes Executive Search for Bioniz Therapeutics, Inc. in Irvine, CA
Executive search firm Toft Group has placed Dr. Paul Frohna as Vice President of Clinical Development at Bioniz Therapeutics, Inc. in Irvine, CA. Dr. Frohna, is a physician-scientist with over 15 years of experience in the biotech industry with expertise in translational medicine, clinical trial design, and clinical and regulatory strategy. Prior to this role, Dr. Frohna was the Vice President of Clinical Development and Translational Medicine at Receptos, Inc. in San Diego, CA.
"Dr. Frohna is uniquely qualified to lead Bioniz' broad development efforts. With the start of our BNZ-1 Phase 1 trials, we have made the important transition into a clinical stage biotechnology company. Few executives in the industry possess Paul's track record of successful drug development of immunotherapies." said Dr. Nazli Azimi, Founder, President and Chief Executive Officer.
Dr. Frohna received his MD from Georgetown University with residency training in Internal Medicine, his PhD in Pharmacology from the University of Pennsylvania, and his Pharmacy Degree with Honors from the University of Texas at Austin.
About Bioniz Therapeutics, Inc.
Bioniz is a biopharmaceutical company leading the discovery and development of first-in-class multi-cytokine inhibitory peptide therapeutics to address immuno-inflammatory diseases and cancer, with an initial focus on orphan diseases that have an immune component. Bioniz leverages its world class expertise in cytokine biology, originating in research conducted at the National Institutes of Health (NIH), to develop a novel approach to selectively inhibit functionally redundant cytokines while leaving the rest of the cytokine network intact. Bioniz’ innovative platform has resulted in multiple peer-reviewed publications in notable scientific journals.